The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Irinotecan Hydrochloride 20 mg/mL concentrate for solution for infusion

Teva B.V.PA1986/068/001

Main Information

Trade NameIrinotecan Hydrochloride 20 mg/mL concentrate for solution for infusion
Active SubstancesIrinotecan hydrochloride trihydrate
Dosage FormConcentrate for solution for infusion
Licence HolderTeva B.V.
Licence NumberPA1986/068/001

Group Information

ATC CodeL01XX Other antineoplastic agents
L01XX19 irinotecan


License statusAuthorised
Licence Issued16/05/2008
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back